首页|ImpriMed Inc. Researchers Update Current Data on Machine Learning (Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma)
ImpriMed Inc. Researchers Update Current Data on Machine Learning (Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
Frontiers Media Sa
Investigators publish new report on artificial intelligence. According to news originating from Mountain View, California, by NewsRx correspondents, research stated, “Dogs with B-cell lymphoma typically respond well to first-line CHOP-based chemotherapy, but there is no standard of care for relapsed patients.” The news editors obtained a quote from the research from ImpriMed Inc.: “To help veterinary oncologists select effective drugs for dogs with lymphoid malignancies such as B-cell lymphoma, we have developed multimodal machine learning models that integrate data from multiple tumor profiling modalities and predict the likelihood of a positive clinical response for 10 commonly used chemotherapy drugs. Here we report on clinical outcomes that occurred after oncologists received a prediction report generated by our models.”
ImpriMed Inc.Mountain ViewCaliforniaUnited StatesNorth and Central AmericaBusinessCyborgsDrugs and TherapiesEmerging TechnologiesMachine Learning
NETL
NSTL
Frontiers Media Sa
